In the era of big data, looking for insights in large datasets has become the norm — and health data are no exception. Combining systems-biology-driven, endophenotype-based analysis of drug targets with large-scale medical claims data points to sildenafil as a potential treatment opportunity for Alzheimer’s disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
11 January 2022
A Correction to this paper has been published: https://doi.org/10.1038/s43587-022-00168-1
References
Fang, J. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00138-z (2021).
Uthayathas, S. et al. Pharmacol. Rep. PR 59, 150–163 (2007).
Sanders, O. J. Alzheimers Dis. Rep. 4, 91–106 (2020).
Gottesman, I. I. & Gould, T. D. Am. J. Psychiatry 160, 636–645 (2003).
Guney, E., Menche, J., Vidal, M. & Barábasi, A.-L. Nat. Commun. 7, 10331 (2016).
Ghiassian, S. D. et al. Sci. Rep. 6, 27414 (2016).
Menche, J. et al. Science 347, 1257601 (2015).
Aguirre-Plans, J. et al. Pharmaceuticals 11, 61 (2018).
Cheng, F. et al. Nat. Commun. 9, 2691 (2018).
Langhauser, F. et al. NPJ Syst. Biol. Appl. 4, 8 (2018).
Aguirre-Plans, J. et al. J. Mol. Biol. 431, 2477–2484 (2019).
Cirillo, D. et al. NPJ Digit. Med. 3, 81 (2020).
Bearden, C. E. & Freimer, N. B. Trends Genet. 22, 306–313 (2006).
Geifman, N., Kennedy, R. E., Schneider, L. S., Buchan, I. & Brinton, R. D. Alzheimers Res. Ther. 10, 4 (2018).
Götz, J., Matamales, M., Götz, N. N., Ittner, L. M. & Eckert, A. Front. Physiol. 3, 320 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.G. is an employee of STALICLA, a clinical-stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders through endophenotyping and artificial intelligence. A.A. is an employee of Accenture.
Rights and permissions
About this article
Cite this article
Guney, E., Athie, A. A needle for Alzheimer’s in a haystack of claims data. Nat Aging 1, 1083–1085 (2021). https://doi.org/10.1038/s43587-021-00139-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-021-00139-y